Can we change the paradigm in children with Non-Alcoholic Fatty Liver disease using Ultrasound Shear wave elastography as a non-invasive point of care tool?

Date Added
March 1st, 2022
PRO Number
Pro00116969
Researcher
Nagraj Kasi

List of Studies


Keywords
Children's Health, Liver
Summary

This investigator-initiated research study supported by a pilot grant from MUSC-Siemens research collaboration, aims to test the feasibility and reproducibility of Ultrasound Shear wave elastography as a point of care tool in screening for hepatic fibrosis and steatosis in children 9-17 years of age with Non-Alcoholic Fatty Liver Disease.

Institution
MUSC
Recruitment Contact
Nagraj Kasi
843-876-0444
kasi@musc.edu

An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)

Date Added
February 10th, 2022
PRO Number
Pro00117076
Researcher
Nagraj Kasi

List of Studies


Keywords
Liver, Pediatrics
Summary

This is an Open-label Extension Phase 3 Study to determine whether a study drug called maralixibat is safe and effective in treating itchy skin (pruritus) in children with Progressive Familial Intrahepatic Cholestasis (PFIC). There is currently no treatment approved for PFIC and available medical approaches have limited success.

Open label means both the investigators and the subjects are aware of the drug or treatment being given

A Phase 3 study is large scale trial to confirm and expand information on safety and usefulness of a new drug.

Subjects who participate in this study will receive the study drug. The dose of the study drug will be gradually increased during the study up to a tolerable dose . Subjects will continue to take the medication for about 26 months. Subjects will have approximately 16 study visits over 26 months in this study. Subjects will also be asked questions about health and complete questionnaires at the study visits and as well as at home. A Physical exam and Liver ultrasound will be performed at some study visits. A blood and urine sample will also be collected at some of the study visits.

It is possible that the maralixibat may or may not improve symptoms from PFIC. Even if there is no benefit, other children may benefit from what is learned in this study.

Institution
MUSC
Recruitment Contact
Kenreka Yeadon
843-792-7965
yeadon@musc.edu



-- OR --